TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10327731
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg, twice a day for 3 months
Study: 1760067
Drug: Dual agent
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual agent therapy (ampicillin and gentamicin)
Study: 1760067
Drug: Triple agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple agent therapy (ampicillin, gentamicin, and clindamycin)
Study: 30782938
Drug: Safety Planning
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Safety Planning Intervention (SPI) with telephone follow-up and treatment as usual, n=80
Study: 30782938
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual, n=40
Study: 16707886
Drug: Intramuscular triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular triamcinolone acetonide (imTA) 40 mg once a month for 6 months followed by 40 mg once every 1.5 months for 1 year (imTA group)
Study: 16707886
Drug: Pulse therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse therapy (PT) using oral prednisone 80 mg for 3 consecutive days once every 3 months (PT group)
Study: 16707886
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (Dex) 0.5 mg/day for 6 months (Dex group)
Study: 8431363
Drug: Qualitator daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitator daily diary card for Quality of Life measurement
Study: 3312789
Drug: Sequential course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential course of 14 days conventional immunosuppression (Lymphocytoglobulin (ALG), azathioprine, steroids) and cyclosporin and steroids thereafter (group A)
Study: 3312789
Drug: Conventional immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppression for 7 days followed by cyclosporin and steroids (group B)
Study: 3312789
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with serum creatinine of less than 2 mg/dl at the time of conversion to cyclosporin
Study: 3312789
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with serum creatinine of more than 2 mg/dl at the time of conversion to cyclosporin
Study: 31425480
Drug: Vemurafenib (monotherapy)
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib (monotherapy)
Study: 31394768
Drug: Hot water
Normalized name: hot water bottle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot water extract of Curcuma longa L. (WEC) 900 mg tablets containing 400 μg bisacurone, 80 μg turmeronol A, and 20 μg turmeronol B
Study: 31394768
Drug: Hot water
Normalized name: hot water bottle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot water extract of Curcuma longa L. (WEC)
Study: 26799907
Drug: NO-FEAR Airlines
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO-FEAR Airlines (Computer-aided Self-help Treatment); includes psychoeducation, exposure through 6 scenarios with images and sounds related to flying; self-applied via Internet.
Study: 21178832
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list (no treatment)
Study: 18513463
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg, 3 times daily
Study: 18513463
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg, 3 times daily + Ezetimibe 10 mg/day
Study: 11434162
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (grade II)
Study: 11434162
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (grade III)
Study: 11434162
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (grade I)
Study: 9720838
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg twice daily zinc therapy for 3 months
Study: 31879782
Drug: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg
Study: 28576285
Drug: High-dose ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ketamine (1.0 mg/kg)
Study: 22047811
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of dexamethasone (2 mg)
Study: 22047811
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of dexamethasone (2 mg)
Study: 22047811
Drug: Liquid vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid vs Tablet
Study: 19957671
Drug: Micro-drill treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-drill treatment
Study: 19957671
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment in PSCO group
Study: 19957671
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment in NLDO group
Study: 19957671
Drug: Micro-drill treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-drill treatment in PSCO group
Study: 19957671
Drug: Micro-drill treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-drill treatment in NLDO group
Study: 19957671
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment complications
Study: 19957671
Drug: Micro-drill treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-drill treatment complications
Study: 16799342
Drug: Supine extubation
Normalized name: ADAPTER,INTUBATION CAREFUSION #1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supine extubation with intravenous lidocaine (group SL)
Study: 8100611
Drug: Zidovudine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (500 mg twice daily)
Study: 29479645
Drug: Total daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total daily sitting time
Study: 18087209
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (rTMS)
Study: 14667881
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist administered from stimulation day 6
Study: 14667881
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (serum P <1.2 ng/mL)
Study: 10978402
Drug: Target Hb
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target Hb of 14 g/dl
Study: 10978402
Drug: Target Hb
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target Hb of 10 g/dl
Study: 8642853
Drug: CI-973 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-973 at MTD of 1000 mg/m2 per course
Study: 8642853
Drug: CI-973 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-973 at doses > or = 1000 mg/m2
Study: 8642853
Drug: CI-973 therapy
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-973 therapy
Study: 1848289
Drug: Sintered hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintered hydroxyapatite implant material
Study: 6229864
Drug: Ipratropium nasal
Normalized name: ipratropium nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium nasal spray
Study: 1441734
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (3 intramuscular injections at months 0, 1, and 2)
Study: 2863799
Drug: ACC‐9447 (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC‐9447 (topical beta adrenergic antagonist)
Study: 24032192
Drug: Common acupuncture
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common acupuncture therapy
Study: 18543482
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with intravenous injection of 20 mg Omeprazole once a day for 3 successive days.
Study: 16415703
Drug: Sertraline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (25 mg/d for 1 week, then 50 mg/d for 15 weeks)
Study: 10818030
Drug: Anticoagulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation treatment (warfarin) after individualised decision analysis
Study: 10818030
Drug: Warfarin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prescription
Study: 8867905
Drug: GL-METF (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GL-METF (2.5 mg glibenclamide and 400 mg metformin)
Study: 8867905
Drug: GL-PHEN (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GL-PHEN (2.5 mg glibenclamide and 25 mg phenformin)
Study: 29366513
Drug: Vibegron 50mg
Normalized name: Vibegron
DrugBank: Vibegron (DB14895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vibegron 50mg once daily
Study: 29366513
Drug: Vibegron 100mg
Normalized name: Vibegron
DrugBank: Vibegron (DB14895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vibegron 100mg once daily
Study: 29366513
Drug: Imidafenacin 0.1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidafenacin 0.1mg twice daily
Study: 22700039
Drug: Galantamine (GAL)
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galantamine (GAL) 8 mg/day
Study: 21029662
Drug: rhTNFR:Fc 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTNFR:Fc 0.4 mg/kg, subcutaneously injected twice weekly
Study: 21029662
Drug: MTX 10
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 10 mg × m(‐2) × w(‐1)
Study: 21029662
Drug: SASP 30‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SASP 30‐50 mg × kg(‐1) × d(‐1) (for intolerance patients)
Study: 8934215
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose administration (75 g)
Study: 8934215
Drug: Pyridostigmine (PST,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (PST, 120 mg)
Study: 31542391
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg and Quercetin 1000 mg for 3 days
Study: 29595449
Drug: Continuous oxygen
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oxygen (3 l/min if baseline oxygen saturation ≤ 93%, 2 l/min if > 93%) for 72 hours after randomisation
Study: 25199313
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg x kg(‐1))
Study: 25199313
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg x kg(‐1)) plus Cooling
Study: 22302296
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg NTG skin spray
Study: 20363999
Drug: CO(2) therapy
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO(2) therapy in addition to routine methods (surgical and/or chemical debridement, advanced dressings)
Study: 10732656
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg b.i.d. (increased to 75 mg b.i.d. from day 15)
Study: 10732656
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg once daily (remained at 50 mg b.i.d. from day 15)
Study: 8887985
Drug: Placebo (1/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1/4 strength preparation of an amino acid mixture)
Study: 3964710
Drug: Diltiazem and
Normalized name: Diltiazem and enalapril only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem and propranolol (120 mg diltiazem and 160 mg propranolol)
Study: 31765046
Drug: elbasvir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: elbasvir (50 mg)/grazoprevir (100 mg) for 8 weeks
Study: 31765046
Drug: elbasvir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: elbasvir (50 mg)/grazoprevir (100 mg) for 12 weeks
Study: 31765046
Drug: elbasvir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: elbasvir (50 mg)/grazoprevir (100 mg) for 12 weeks (treatment-experienced)
Study: 31675351
Drug: Corticosteroid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (1 mL methylprednisolone 40 mg/mL) + local anaesthetic (1 mL bupivacaine 5 mg/mL)
Study: 23756080
Drug: 1-second benzocaine
Normalized name: benzocaine 0.1 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-second benzocaine spray before upper endoscopy
Study: 23756080
Drug: No spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: No spray (control group)
Study: 21629111
Drug: Topical negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical negative pressure therapy
Study: 21629111
Drug: Conventional dressing
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dressing therapy with sodium hypochlorite
Study: 19793724
Drug: Intravenous diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diamorphine (0.1 mg/kg)
Study: 16966534
Drug: Rivastigmine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (3 to 6 mg/day)
Study: 9701294
Drug: Hydrocodone-acetaminophen (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone-acetaminophen (5 mg hydrocodone with 500 mg acetaminophen)
Study: 2597854
Drug: Short educational
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short educational programme or routine treatment (Control)
Study: 30281141
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser treatment followed by topical application of sodium stibogluconate
Study: 30281141
Drug: Intralesional injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injections of sodium stibogluconate
Study: 21447654
Drug: Tyramine infusion
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyramine infusion during exercise
Study: 21447654
Drug: Combined ATP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ATP and tyramine infusions
Study: 18331374
Drug: Carbohydrate-rich drink
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-rich drink (400 ml, 12.5%) with paracetamol 1.5 g
Study: 11410122
Drug: Adrenomedullin (AM)
Normalized name: Adrenomedullin
DrugBank: Adrenomedullin (DB19102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenomedullin (AM) infusion (4 pmol.min(‐1).kg(‐1))
Study: 9390695
Drug: New antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiepileptic drugs and nonpharmacologic treatments
Study: 8430049
Drug: Buccal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal delivery of diclofenac sodium from a prototype hydrogel
Study: 8430049
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) infusion of diclofenac sodium
Study: 29447248
Drug: Supported park
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supported park prescription (physician counseling, maps, journal, pedometer, phone and text reminders, three weekly family nature outings with free transportation, food, and programming)
Study: 29447248
Drug: Independent park
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent park prescription (physician counseling, maps, journal, pedometer)
Study: 19910619
Drug: Pregabalin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (300 mg before TKA and 150-50 mg twice daily for 14 days after TKA)
Study: 18303706
Drug: CR plus
Normalized name: Amino Acids/Chromium Oral Tablet [CR PLUS PROTEIN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR plus nicotine patch (21 mg, CR+NRT) for 16 weeks
Study: 12004315
Drug: 308-nm xenon-chloride
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm xenon-chloride excimer laser, treated 3 times a week for a maximum of 12 treatments
Study: 10207634
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg of aspirin per day for 3 months
Study: 10207634
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet for 3 months (washout period)
Study: 7829623
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms iodide plus 100 micrograms L‐T4/day
Study: 2199628
Drug: Aztreonam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (2 g i.m.)
Study: 2199628
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 ml lidocaine 2%)
Study: 23051740
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blocker (ARB) plus calcium channel blocker (CCB) combination
Study: 17893454
Drug: Fiberoptic intubation
Normalized name: ADAPTER,INTUBATION CAREFUSION #1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiberoptic intubation with a flexible silicone tube without neuromuscular blocking agents
Study: 17893454
Drug: Orotracheal intubation
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orotracheal intubation with a polyvinyl chloride tube after induction with neuromuscular blocking agents
Study: 10329078
Drug: Dalteparin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (low molecular weight heparin)
Study: 6803977
Drug: Chlorpromazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (1 mg/kg or 4 mg/kg either by mouth or intramuscularly)
Study: 23462262
Drug: Cefazolin 4
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin 4 g before skin incision and 2 g during skin closure
Study: 22039966
Drug: Daily multivitamin
Normalized name: DAILY MULTIVITAMIN TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multivitamin supplement
Study: 18270356
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (second- and third-line programs)
Study: 10671850
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac 10 mg made up to 2 ml with saline
Study: 1490503
Drug: Conventional Madopar
Normalized name: Madopar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Madopar capsules
Study: 27021606
Drug: MPH ERCT
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPH ERCT 40 mg
Study: 27021606
Drug: IR MPH
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IR MPH 40 mg
Study: 19952781
Drug: Riboflavin 1.6
Normalized name: riboflavin 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin 1.6 mg per day for 16 weeks
Study: 18782344
Drug: Aripiprazole (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (up to 15 mg)
Study: 12745487
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment and nicotine replacement therapy (gum, patch, or inhaler) to reduce smoking by 50% over 4 weeks
Study: 11910264
Drug: 5-HTP 100
Normalized name: CVS 5-HTP 100mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HTP 100 mg with carbidopa 100 mg and 50 mg
Study: 11910264
Drug: 5-HTP 100
Normalized name: CVS 5-HTP 100mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HTP 100 mg
Study: 7488373
Drug: Ciprofloxacin hydrochloride
Normalized name: Ciprofloxacin Hydrochloride
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin hydrochloride (200 mg/mL), 24 patients
Study: 7488373
Drug: Gentamicin sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin sulfate (5 mg/mL), 20 patients
Study: 7036816
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir at 750 mg/m2 body surface area per day for 7 days
Study: 12185774
Drug: Specialist nursing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specialist nursing intervention; details on dosage and duration not available.
Study: 9526211
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg enoxaparin subcutaneously once per day
Study: 9526211
Drug: 5,000 IU
Normalized name: bleopmycin 15,000 IU Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 IU heparin sodium subcutaneously 3 times daily (increased to 7,500 IU if PTT did not reach 40 seconds)
Study: 26567123
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment for type 2 diabetes
Study: 26567123
Drug: Dipeptidyl peptidase‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipeptidyl peptidase‐4 inhibitors
Study: 26391130
Drug: Soluble intercellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble intercellular adhesion molecule-1 (quartiles 2-4)
Study: 26391130
Drug: Soluble intercellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble intercellular adhesion molecule-1 (multivariable adjustment)
Study: 23070939
Drug: Buffered solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered solution with mild alkalinity (pH 7.2-7.4)
Study: 23070939
Drug: Buffered solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered solution with alkalinity (pH 8.2-8.4)
Study: 23070939
Drug: Nonbuffered solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonbuffered solution (pH 6.2-6.4)
Study: 15161116
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate injection